Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
Lovastatin Workflow for HMG-CoA Reductase Assays
2026-08-30
Build more interpretable cholesterol-metabolism experiments with Lovastatin, from dose–response screening to macrophage efferocytosis and fibroblast apoptosis workflows. This guide combines practical formulation advice with a plant-development study that illustrates how orthogonal pathway and phenotype readouts can strengthen mechanism-focused research.
Tropifexor: Dissecting FXR and Nutrient Signals
2026-08-29
Tropifexor (LJN452) offers a precise way to separate FXR-driven epithelial responses from nutrient-derived hepatic signaling. This article uses triacetin absorption research to build a more rigorous experimental framework for intestinal barrier and metabolic disease studies.
Ellagic acid: A Rigorous CK2 Assay Strategy
2026-08-28
Ellagic acid is a selective CK2 probe with applications spanning cancer biology research, oxidative stress assays, and apoptosis studies. This guide develops a senescence-aware validation framework that distinguishes target engagement from downstream phenotype and avoids overinterpreting machine-learning-derived senolytic findings.
Dasatinib Monohydrate: Mechanism and Research Use
2026-08-28
Dasatinib Monohydrate (BMS-354825) is an ATP-competitive, multitargeted tyrosine kinase inhibitor with activity against BCR-ABL, SRC, KIT, and PDGFR. Its strongest research rationale is imatinib-resistant BCR-ABL inhibition in CML and Ph-positive acute lymphoblastic leukemia, while patient-derived assembloids offer a complementary framework for studying stromal effects on drug response.
Mitochondrial Calcium Signaling Represses Ferroptosis
2026-08-27
The reference study identifies a mechanistic connection between mitochondrial calcium uptake through MCU and GPX4 activity, showing that calcium-dependent acetyl-CoA production supports GPX4 acetylation and ferroptosis suppression. Its combination of genetic, structural, mutational, animal, and cancer-model evidence provides a framework for interpreting mitochondrial metabolism in ferroptosis assays and tumor biology.
Liproxstatin-1 HCl: Reliable Ferroptosis Assays
2026-08-27
This scenario-based guide shows how Liproxstatin-1 HCl (SKU B8221) can improve interpretation of viability, cytotoxicity, and ferroptosis experiments through pathway-selective rescue, practical formulation guidance, and appropriate controls. It connects product data with mechanistic evidence while emphasizing reproducible assay design and cautious data interpretation.
IDO1 Inhibition and Tumor-Protective STAT3 Activation
2026-08-26
A 2024 Journal of Immunology study shows that apo-IDO1 inhibition can activate antitumor immune cells while simultaneously inducing an IL-6–JAK2–STAT3 survival program in tumor cells. The work provides a mechanistic explanation for unexpected resistance to IDO1-targeted therapy and supports testing IDO1 blockade alongside inhibitors of tumor-intrinsic cytokine signaling.
BRCAness and Olaparib Sensitivity in Mesothelioma
2026-08-26
Borchert et al. connected homologous recombination repair defects, BAP1 mutation, and olaparib response in malignant pleural mesothelioma models. Their combination of cell-based treatment assays with gene-expression profiling of 91 clinical samples suggests a framework for selecting DNA-repair-directed therapies, while also highlighting the need for clinical validation.
MK-2206 and the Metabolic Logic of Akt Biology
2026-08-25
A translational framework for using MK-2206 dihydrochloride to connect Akt target engagement with apoptosis, cancer biology, and Wnt-driven metabolic remodeling.
HyperFusion™ for Mechanistic Neurobiology PCR
2026-08-25
Discover how a proofreading DNA polymerase can protect sequence integrity in neurobiology assays. This article connects the C. elegans pheromone–neurodegeneration study to assay design, cloning, genotyping, and sequencing decisions using HyperFusion™.
U 46619: From TP Signaling to Translational Insight
2026-08-24
U 46619 is more than a platelet agonist: it is a mechanistic tool for connecting TP-receptor signaling with platelet activation, vascular tone, renal hemodynamics, and translational study design.
Spermine Tetrahydrochloride: From Charge to Translation
2026-08-24
A mechanistic and strategic guide to using Spermine tetrahydrochloride in membrane-stability assays, protein crystallization, and polyphosphazene nanoparticle workflows—while defining the evidence boundaries for neuroscience and translational research.
MCL-1 Dependence in Breast Cancer: Apoptotic Function
2026-08-23
This 2021 Cell Death & Differentiation study shows that established breast tumors depend on MCL-1 primarily because of its canonical anti-apoptotic activity. Genetic deletion and pharmacological inhibition both required BAX/BAK to produce anti-tumor effects, while MCL-1 also supported breast cancer stem cell activity.
Chronic Stress, Mitochondria, and Depression-Like Behavior
2026-08-22
A 2025 study in Psychoneuroendocrinology connects chronic unpredictable mild stress with mitochondrial dysfunction and neuroinflammation in the rat hippocampus and prefrontal cortex. Its MnTBAP intervention experiment goes beyond association by showing that mitochondrial redox protection can alleviate stress-induced depression-like behavior, while also highlighting important limits in translating an intracerebroventricular animal study to human depression.
DiscoveryProbe FDA-approved Drug Library for OA
2026-08-22
Translate the OSCAR–PPARγ osteoarthritis mechanism into a practical screening workflow with a 2,320-compound approved-drug collection. Use orthogonal binding, viability, imaging, and transcriptional assays to distinguish genuine pathway modulation from nonspecific toxicity or assay interference.
8519 records 8/568 page Previous Next First page 上5页 678910 下5页 Last page